Comparative Pharmacology
Head-to-head clinical analysis: THYROGEN versus XYLOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROGEN versus XYLOSE.
THYROGEN vs XYLOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human thyroid-stimulating hormone (TSH) that binds to TSH receptors on thyroid follicular cells, stimulating iodine uptake, thyroglobulin synthesis, and release of thyroid hormones.
Xylose is a pentose sugar that is absorbed in the small intestine via passive diffusion and active transport. It is used to assess intestinal mucosal integrity; its absorption reflects the function of the enterocytes. After absorption, it is not metabolized and is excreted unchanged in urine, making it a marker for intestinal absorption and renal function.
0.9 mg intramuscular injection every 24 hours for 2 doses, or 1.2 mg orally as a single dose.
Adults: 25 g orally in 500 mL water, administered as a single dose for D-xylose absorption test.
None Documented
None Documented
12-15 hours (terminal elimination half-life in patients with normal renal function; may be prolonged in renal impairment). Clinically, TSH levels peak by 3 hours after IM injection and return to baseline by 24-48 hours.
Terminal elimination half-life: 1.2-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 10 hours).
Primarily renal (thyrotropin is a glycoprotein hormone; intact hormone is minimally excreted unchanged; metabolic degradation products are eliminated renally). After IV administration, approximately 96% of the dose is recovered in urine within 24 hours as low molecular weight degradation products. Biliary/fecal excretion is negligible (<1%).
Renal: approximately 85-90% eliminated unchanged in urine; biliary/fecal: negligible (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent